11th Annual Controversies in Hematologic Malignancies Symposium

May 7, 2022

This one-day symposium will raise and address the most challenging questions in current clinical practice for hematologic malignancy. Topics will include navigating frontline therapies in CLL, incorporating new approvals in DLBCL into practice, bispecifics and novel immune treatments in myeloma, sickle cell gene therapy, HMA alternatives for MDS/MPN patients and much more

Target Audience

Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses and Allied Health Professionals

Learning Objectives

Participants who engage in this educational intervention will be able to: 

  • Identify current best practice evidence-based guidelines for the management of myelodysplastic syndrome and where to find updates. References to websites will be provided for clinicians and their patients.
  • Describe evidence-based recommendations designed to diagnose and improve management of chronic lymphocytic leukemia and monoclonal gammopathy of undetermined significance (MGUS), which learners will be asked to identify in the post-conference assessment
  • Treatment and management for R/R Large B-Cell CAR-T therapy. Attendees will be able to list challenges and treatment options for patients with R/R Large B-Cell Lymphoma based on updated guidelines.
Additional information
AttachmentSize
PDF icon Beyond CART - FA - MS.pdf851.35 KB
PDF icon Conrad & Johannes - Frailty Prevention in Inpatient Hematology Oncology Patients.pdf507.44 KB
PDF icon Costa - Promise of Bispecifics and CAR-T in MM.pdf4.8 MB
PDF icon Gene therapy SCD-EAPEN.pdf788.85 KB
PDF icon Hamadani - Heme Malignancy Symposium April 2022.pdf1.6 MB
PDF icon Jain_Frontline CLL_MCW_May 2022.pdf2.23 MB
PDF icon Lorge - MKE Heme Symposium 5.4.22.pdf1.53 MB
PDF icon Mohan - Smoldering multiple myeloma4202022.pdf2.97 MB
PDF icon Runaas - Treatment for MDS + MPN 5.7.2022.pdf922.39 KB

Contact

Name: 
Dan Bullock
Phone Number: 
+1 (414) 805-4617
Email: 
danbullock@mcw.edu
Course summary
Available credit: 
  • 4.25 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 4.25 Hours of Participation
    Hours of Participation credit.
Course opens: 
02/08/2022
Course expires: 
12/31/2022
Event starts: 
05/07/2022 - 8:00am CDT
Event ends: 
05/07/2022 - 5:00pm CDT
Cost:
$0.00
Add to calendar: 
Rating: 
0

AGENDA

7:30 – 8:25 a.m. Check in
8:25 – 8:30 a.m. Introduction
 
Lymphoma Block:
8:30 – 8:50 a.m. Second Line Treatment for Aggressive B-cell Lymphomas: CAR-T for all? (MEHDI HAMADANI)  
8:50 – 9:30 a.m. New Advances in Aggressive Lymphomas Beyond CAR-T (FARRUKH AWAN)
9:30 – 9:45 a.m. Panel Q&A with speakers (HAMADANI and AWAN)
 
9:45 – 10:00 a.m. Break
 
Leukemia Block:
10:00 – 10:20 a.m. Treatment beyond HMAs in MDS/MPNs (LYNDSEY RUNAAS)
10:20 – 11:00 a.m. Navigating Frontline Therapies in CLL (NITIN JAIN)
11:00 – 11:15 a.m. Panel Q&A with speakers (RUNAAS & JAIN)
 
11:15 – 11:30 a.m. Break
 
11:30 – Noon  Breakout Sessions:
  • Novel oral agents (AARON LORGE)
  • Inpatient Experience: OT/PT During Prolonged Hospital Stay (CATHERINE CONRAD & SCOTT JOHANNES)
  • Sickle Cell Gene Therapy (MARY EAPEN)
 
12:00 – 12:45 p.m. Lunch
 
Myeloma Block:
12:45 – 1:05 p.m.  Updates in the Management of Smoldering Myeloma (MEERA MOHAN) 
1:05 – 1:45 p.m.  Promise of Bispecifics and CAR-T in MM (LUCIANO COSTA)
1:45 – 2:00 p.m.  Panel Q&A with speakers (MOHAN and COSTA)
 
2:00 p.m. Adjourn

 

Hilton- Downtown Milwaukee
United States

Guest Speakers

Farrukh Awan, MD
Associate Professor, Internal Medicine
Director, Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center

Luciano Costa, MD, PhD
Associate Director for Clinical Research
O'Neal Comprehensive Cancer Center
Professor, Department of Medicine
University of Alabama at Birmingham

Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
MD Anderson Cancer Center

Froedtert and the Medical College of Wisconsin Speakers

Mary Eapen, MRCPI, MS, MBBS
Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Mehdi Hamadani, MD
Professor of Internal Medicine
Division of Hematology & Oncology
Medical College of Wisconsin 

Aaron Lorge, PharmD
Oncology Pharmacist
Froedtert & The Medical College of Wisconsin

Meera Mohan, MD, MS, FACP
Associate Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Lyndsey Runaas, MD
Assistant Professor of Medicine
Division of Hematology & Oncology
Medical College of Wisconsin

Catherine Conrad, OTR/L
Froedtert & The Medical College of Wisconsin

Scott Johannes, DPT
Froedtert & The Medical College of Wisconsin

Planning Committee

Sameem Abedin, MD
Co-Program Director
Assistant Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin 

Guru Subramanian Guru Murthy, MD, MS
Co-Program Director
Assistant Professor of Medicine
Division of Hematology and Oncology
Medical College of Wisconsin

Dan Bullock
Education Program Coordinator
Division of Hematology and Oncology
Medical College of Wisconsin

Catherine Skoog, PA-C
Physician Assistant
Division of Hematology and Oncology
Medical College of Wisconsin

In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.

Meera Mohan, MD, MS, FACP
Catherine Conrad, DPT
Scott Johannes, DPT
Aaron Lorge, PharmD
 
NameCompanyRole
Luciano Costa, MD, PhDAmgen, Bristol Myers Squibb, Janssen BiotechConsultant
   
   

In accordance with the ACCME® standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.

 

ACCME Accreditation Statement: 

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

AMA Credit Designation Statement: 

The Medical College of Wisconsin designates this for a maximum of 4.25 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Hours of Participation for Allied Health Care Professionals: 

The Medical College of Wisconsin designates this activity for up to 4.25 hours of participation for continuing education for allied health professionals.  

Available Credit

  • 4.25 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 4.25 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.